Sun Pharma’s R&D spin off unit SPARC has conducted three clinical product trials
Sun Pharma
Hyderabad: Sun Pharma’s R&D spin off unit SPARC has conducted three clinical product trials in the US and is planning to have its own innovative product registered in the next two to three years in the US, informed founder and managing director Sun Pharma Dilip Shanghvi.
Delivering the valedictory address of the IMC conclave in ISB here on Thursday, Mr Shanghvi said, “Under our Sun Pharma Advance Research Company (SPARC), we are conducting three product trials in the US and in the next two to three years we should be having our own product registered in the US. This will in a way validate our belief that one need not spend $2.5 billion in research to bring innovation and differentiated products to meet unmet demands.”
If the product gets registered in US, then Sun Pharma will be one of few Indian pharma companies to have its own drug registered in the US, although other pharma companies have also done so in the US, informed analysts.
Talking about how he has grown the company in the last three decades, Mr Shanghvi modestly said that he could have done better work and he is ‘reasonably satisfied’. He also said that although the industry faces an attrition rate of 30 per cent among medical reps, Sun Pharma has an attrition of only six to seven per cent.
On a lighter vein, the self-made billionaire said that although Hyderabad is the hub of pharmaceutical companies, yet they are not able protect their process confidentiality, “however we have more than 50 products where we are the only company other than the innovator who makes them”.
Commenting further on the recent Food Safety and Standards Authority of India regulations, Mr Shanghvi said that the authorities were creating unnecessary controversy. “The food processing industry needs clearly defined rules so that investment comes into this sector and this kind of controversy will only deter investment,” he added.
( Source : deccan chronicle )
Next Story
